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Sangster, Andrea DVM, MS, Purdue University, December 2014.  Review of the 
pathophysiology of acute spinal cord injury and investigation into the use of urine 3-
HPMA as a novel biomarker of secondary injury after naturally occurring acute spinal 
cord injury in the dog.  Major Professors: Robin T. Bentley and Riyi Shi.  
 
Acute spinal cord injury (ASCI) has two pathophysiological stages of injury: the primary 
injury and the secondary injury cascade.  Primary injury includes the initial or mechanical 
insult to the spinal cord. Secondary injury is a cascade of biochemical events that 
propagates damage of adjacent, healthy tissue increasing the overall volume of spinal 
cord tissue that is affected.  Acrolein is a toxic byproduct of lipid peroxidation produced 
during secondary injury.  A metabolite of acrolein-glutathione adduct found in urine, 3-
HPMA, has recently been shown to increase after spinal cord injury in a rat model.  The 
aim of our study was to apply this urine 3-HPMA assay to dogs to indirectly quantify 
acrolein levels resulting from ASCI due to intervertebral disc herniation (IVDH).  Urine 
was collected from ten client-owned dogs with ASCI upon presentation to PUVTH and 
analyzed for the acrolein metabolite, 3-HPMA per gram of creatinine.  These 
concentrations were compared with urinary 3-HPMA levels from 10 healthy, control 
dogs.  Mean urine 3-HPMA of ASCI dogs with IVDH (8.52 μmol 3-HPMA/g Cre) was 
significantly higher than the mean from control dogs (3.28 μmol 3-HPMA/g Cre).  
Therefore, urine 3-HPMA is higher in dogs after ASCI due to IVDH therefore supporting 
an important role of lipid peroxidation in canine ASCI.  This study supports the use of
    vi
 urine 3-HPMA in future clinical trials to measure the effect of therapeutic intervention 
targeted at reducing acrolein concentration after ASCI.
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Acute spinal cord injury (ASCI) has debilitating and permanent consequences for 
companion animals and humans.  Intervertebral disc herniation, fracture and luxation are 
a few of the pathologic mechanisms for spinal cord injury seen most commonly in 
companion animals.  These can lead to severe functional deficits of paralysis, urinary and 
fecal incontinence and may ultimately result in euthanasia.  In order of decreasing 
frequency, acute intervertebral disc herniation, fibrocartilagenous emboli and trauma are 
the most common causes for ASCI in dogs.1  ASCI accounts for the approximately 2% of 
veterinary patients seen in teaching hospitals across the United States and severe SCI is 
the cause of death for one in one hundred dogs.2  These figures are worse for certain 
breeds because of breed predilection.  For example, the lifetime prevalence of 
intervertebral disc herniation in miniature dachshunds is approximately 20% of the breed 
population.3   
Approximately 2.5 million people are living with the devastating and permanent 
effects of ASCI worldwide with 130,000 new injuries occurring each year.4  Young 
adults are especially affected by complete SCI secondary to motor vehicle accidents, 
recreational sporting accidents or violent attacks. With only limited recovery possible 
after complete spinal cord injury in people, and a life long cost of care estimate reaching 
upwards of three million dollars per individual, novel and successful treatment options 
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for these severe injuries would dramatically benefit many dogs and people as well as our 
community as a whole.5 
Tremendous advances in the understanding of the pathophysiology of ASCI have 
been made in the last few decades.  However, translating that knowledge into effective 
therapeutic remedies that prevent or reverse lifelong paralysis remains a goal for which 
researchers and clinicians continue to strive.  Novel approaches continue to be attempted 
but have not yet consistently or irrefutably changed the expected clinical outcome for 
patients.6-9  This may be in part due to the complexity of the pathophysiology of SCI.10   
A non-invasive biomarker of acute spinal cord injury would provide researchers 
and clinicians alike an objective method of measurement to better evaluate the efficacy of 
treatments that target the biochemical effects of spinal cord injury.  The purpose of this 
thesis is to introduce the pathophysiology of ASCI to readers with an emphasis on 
oxidative injury and acrolein toxicity, discuss a study performed at Purdue University 
Veterinary Teaching Hospital that investigated the novel use of a urine assay of a 
metabolite of acrolein and its use as a biomarker of ASCI in dogs, and present possible 
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CHAPTER 2: LITERATURE REVIEW 
 
Review of the Pathophysiology of Acute Spinal Cord Injury 
Within minutes of severe spinal cord trauma, a progressive and self-destructive 
series of pathological events occurs.  Hemorrhagic necrosis leading to eventual cavitation 
of the central grey matter after contusive injury has been described as early as 7 days but 
may continue to worsen and form larger cystic cavities by 2 weeks.1  Degeneration of 
white matter at the epicenter as well as adjacent white matter tissue degeneration rostrally 
and caudally may be seen within one day of injury.2,3 An expanding volume of tissue 
destruction has been shown to continue to occur for days to even months following injury 
in rats and primates.3  In a rodent compressive injury model, 44% of epicenter neurons 
were lost 1 day following injury, 73% of neurons were lost by 3 days after injury and 
81% loss was noted by 30 days post injury.4  The author of this study suggested that 
compressive injury leads to a more protracted timeline and extent of neuronal loss than 
contusive injury despite both types of forces leading to progressive injury.  Fehlings 
found that the degree of axonal loss and recovery of neurological function after injury are 
directly related to the severity of the force of injury.5  Because astrocytes are more 
resistant to injury, they remain present to form scar like tissue around the defect while 
oligodendrocytes are more susceptible to injury and undergo apoptosis.  Ultimately what 
remains after severe spinal cord injury is a large centrally located fluid-filled cyst with
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surrounding astrocytosis and thin layer of subpial white matter tracts 6, although species 
variation does exist.  An animal’s neurological function with such an injury may be 
determined by the percentage of white matter tracts left intact.  It has been suggested that 
10-15% of the original tissue mass is necessary for functional recovery although this 
estimate varies somewhat in experimental studies.5 
It is now well recognized that two main phases occur after ASCI: primary and 
secondary injury.  Primary injury to the spinal cord is characterized by the mechanical 
insult of the initial traumatic injury.  The most common type of ASCI in dogs and 
humans is a combination of concussive, contusive and compressive trauma secondary to 
displacement of some component of the vertebral column causing both immediate injury 
and persistent compression.7,8  Other common forces in primary injury include shearing, 
laceration, stretching and acceleration-deceleration injuries.8,9  Direct trauma to neurons 
and glia occur as well as vascular compromise.  This incites secondary injury, 
characterized by a cascade of biochemical events that leads to an expanding area of tissue 
damage beyond the borders of the initial lesion.10,11  The secondary injury phase involves 
further vascular compromise, excitotoxicity, ion dysregulation, reactive oxygen species 
production, and inflammation.  These processes result in apoptosis and necrosis of 
adjacent neurons and glial cells.   
ASCI may also be temporally differentiated into immediate, acute, subacute and 
chronic processes with secondary injury events predominating the acute phase and 
beyond.11,12  The immediate phase occurs within 2 hours of injury, acute phase has been 
described between 2 and 48 hours of injury, subacute denotes processes that occur 
between 48 hours and 14 days of injury and chronic events manifest after 2 weeks of the 
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initial insult and may continue on for many months.12  It is of great importance to 
consider the pathophysiological timeline of SCI as well as the effective time and duration 
of application for a given therapeutic intervention when investigating potential drugs that 
may be translated into clinical trials.13  Many experimental studies that have shown 
benefit with therapeutics have failed to translate those successful outcomes to clinical 
trials of naturally occurring injury.13-15  Although a multitude of variables exist that could 
account for this loss of efficacy in translation, temporal intervention is one of them.  As a 
result, secondary injury has been the focus of much research.  A temporal understanding 
of the course of secondary injury events will hopefully allow for therapeutics that target 
the biochemical processes that correspond with the time that patients are actually 
presented for medical care to be the focus of further investigations.  
 
Primary Injury 
Primary injury does not usually completely transect all axons in the transverse 
plane but can lead to variable levels of necrosis of neurons.  Based on animal studies, 
some axons, possibly those that are smaller in diameter and are near the periphery of the 
cord, are likely to be spared in many injuries.16  As a result, therapies aimed at 
remyelination of spared axons to improve conduction and therefore functional outcome 
for individual patients is an area of promise.   
Intervertebral disc herniation is the most common type of ASCI seen in dogs and 
leads to the aforementioned concussive, contusive and compressive types of lesion.10,17,18  
The initial impact of the disc herniation may cause hemorrhage and ischemia as well as a 
concussive injury to the spinal cord.  Subsequent compression of the spinal cord by disc 
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material causes direct damage to neurons and glia by disrupting cell membranes and 
causing further vascular disruption/occlusion leading to ischemia.7 Edema and swelling 
ensue and perpetuate poor blood flow to the injured tissue.  Immediate activation of 
microglial cells initiates the up-regulation of proinflammatory cytokines TNFα and IL-β 
that enhance vascular permeability.19  Extracellular glutamate and other amino acid 
concentrations increase within minutes of trauma, the degree of which is directly related 
to the severity of injury.20 
Current goals of treatment for primary injury include maintaining adequate 
perfusion to the injured spinal cord tissue as well as surgically relieving any persistent 
compression and correcting any vertebral instability that could lead to continued trauma.  
Whether the timing of surgical intervention relative to the injury makes a difference in 
neurological outcome has long been somewhat controversial.  However, findings from a 
large human meta-analysis supported very early intervention leading to better 
neurological outcomes.21  This led to a recent human, multicenter, prospective cohort 
study known as STASCIS that found surgical decompression prior to 24 hours after SCI 
was associated with a significantly improved functional outcome.22   
Beyond early surgical decompression, there are not many effective therapeutic 
options available to lessen the damage that occurs to the cord during the primary injury 
phase.  Once a patient is presented to the hospital for treatment, the earliest possible 
therapeutic intervention would likely be implemented during the secondary injury 
cascade.  As a result, secondary injury has been implicated as the more important target 




Hemorrhage, edema, and inflammation that begin during primary injury, and 
continue to proceed during the acute phase of secondary injury.  In addition, other 
processes arise including ion dysregulation, glutamate accumulation resulting in 
excitotoxicity, lipid peroxidation with acrolein production and reactive oxygen species 
(ROS) production.  Apoptosis of oligodendrocytes results leading to demyelination of 
axons and conduction failure.  Necrosis of neurons and glial cells may also result in an 
enlarged zone of destruction as well as the propagation of inflammation, as neuronal and 
glial cell lysis releases pro-inflammatory agents.23  Astrocytes are also affected but 
appear more resistant to contusive injury than neurons and oligodendroglia.24 
Disruption of perfusion to the site of tissue damage is a central theme to primary 
and secondary injury.  It has been shown that loss of perfusion to cord tissue is directly 
related to the severity of injury and that perfusion worsens with time after injury.25  
Immediately after injury, hemorrhage is detected in the central zone that ultimately leads 
to an area of neuronal necrosis due to infarction.25  Not only does direct trauma 
compromise the microvasculature at this site but progressive edema leads to increased 
interstitial pressure and reduced perfusion to the spinal cord via small blood vessels.  
Other microcirculatory defects that contribute to diminished perfusion include 
vasospasm, thrombosis, neurogenic shock and loss of autoregulation.  Neurogenic shock 
has been described in experimental rat models of acute spinal cord injury evidenced by 
decreased cardiac output and systemic hypotension thought to result from reduced 
sympathetic tone and possibly direct myocardial injury.25,26  The central nervous system 
normally benefits from an autoregulatory system that is able to maintain perfusion to 
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spinal cord tissue despite variations in systemic blood pressure.  Loss of this 
autoregulation becomes a concern after spinal cord injury, leaving the spinal cord tissue 
that is already compromised at risk to suffer reduced perfusion due to systemic 
hypotension.  Systemic hypotension in the face of loss of autoregulation would greatly 
compound the level of tissue ischemia at the site of injury.  Worsening ischemia leads to 
further cytotoxic edema and the cycle continues.  Many patients that have experienced 
traumatic injuries experience systemic hypotension therefore patients with CNS lesions 
must be treated with this in mind and normotension should be maintained.18,25 
In this thesis, the basic components of the secondary injury biochemical cascade 
will be discussed, with subsequent discussion of oxidative stress and acrolein cytotoxicity 
as the main focus of the clinical study.   
 
Cytokines and Cellular Inflammatory Response 
 The effects of the inflammatory response on the spinal cord after injury are not 
yet as well understood or agreed upon as some of the other secondary injury processes.  
The inflammatory reaction is complex with many of the inflammatory constituents, 
including microglia, cytokines, non-resident macrophages, lymphocytes and neutrophils 
having multiple functions.  Some of these processes have been interpreted as detrimental 
due to worsening secondary injury and others have been found to be beneficial for 
healing by removing cellular debris and promoting regeneration.23,27  In addition, the 
timing of activity and relative importance of these various cell types and compounds 
differ among species and even among strains within species of rodent models.19  
Unfortunately, there are substantially fewer data regarding immune responses to naturally 
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occurring SCI in companion animals and humans compared with rodent models.28  As a 
result, although immune manipulation to improve neurologic functional outcome after 
injury is a goal of many experimental studies, it is not likely to be the subject of clinical 
trials in the immediate future.  However, as the inflammatory response becomes better 
elucidated in each species, it may become an important area for intervention.  
 The complexity and multiplicity of functions of individual components of the 
immune response make a comprehensive understanding of its effects on the spinal cord 
after injury daunting.   Within the neuroinflammatory response, neutrophils are thought to 
contribute to tissue damage and rodent studies have shown that blocking neutrophil 
infiltration lessens the extent of secondary injury.29-32  
Microglia are resident CNS macrophages that become activated after injury and 
are therefore a predominant cell seen in all species after ASCI.  Microglia may be 
destructive to adjacent tissue early in the inflammatory response but may also have a 
beneficial effect later in the course of inflammation.  Both neutrophils and macrophages 
have the potential to cause further damage to SC tissue through the generation of reactive 
oxygen species that lead to lipid peroxidation and its toxic byproducts.33   In fact, 
microglial production of reactive oxygen species seemed to be directly related to severity 
of clinical signs in one study of naturally occurring canine SCI.34  One study found that 
markers for oxidative injury produced by neutrophils and macrophages were increased 1-
3 days after human spinal cord injury, suggesting that these inflammatory cells may 
directly damage adjacent cells via lipid peroxidation.35   Microglia can also perpetuate 
inflammation due to cytokine release.   However, they are also thought to promote 
healing and repair by secreting neurotrophic and axonal growth factors and carrying out 
 12 
the phagocytic task of cleaning up necrotic cells and debris at the epicenter of the 
lesion.36,37   Removing debris helps to promote healing as it creates a path for axonal 
budding to occur and removes myelin and myelin inhibitory proteins that can suppress 
axonal regrowth.  In addition, a circular argument is made that removal of lipid 
membranes from the injury site by phagocytosis may reduce the secondary damage 
caused by lipid peroxidation.33  
The overall effect of lymphocytes in secondary injury remains controversial.  
Some studies have suggested a beneficial effect and others have supported improved 
outcome when T-lymphocyte infiltration is suppressed.38  
 The timing and type of immune response varies among species.  Neutrophil 
infiltration immediately after injury is common to rats, mice and humans however 
variation in the timing and duration of peak concentration of cells exists between these 
species.  Neutrophil numbers are maximally expressed 1-3 days after injury and remain 
increased for up to 10 days in humans.35  Neutrophil numbers are similarly high for 1 to 2 
days in rats following SCI, however in mice, they peak 3-14 days post injury and may 
remain increased for several weeks.29,35,39  Interestingly, in a histopathological study of 
canine spinal cords after naturally occurring injury, neutrophil infiltration was not 
appreciated.40  However, no immunostaining was performed in that study, which may 
have detected neutrophils better than morphological evaluation alone.  Immunostaining 
was thought to explain the increased number of neutrophils found in a more recent study 
compared with two other human studies of SCI that did not use similar techniques.35,41,42  
Common to all species discussed is the microglial/macrophage response.  Microglial 
activation occurs immediately after injury and macrophage numbers peak at 5-10 days in 
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dogs, rodents and humans.27,34,35,  Lymphocyte infiltration appears to be a prominent 
component of the neuroinflammatory response in mice but does not occur as significantly 
in dogs, rats or humans.  T cell infiltration into the injured spinal cord has been shown to 
peak 3-7 days after injury in rat models but is delayed until 7-14 days in mice.39,43  This is 
in contrast to findings in humans, which seem to exclude a major role by T and B cells 
after SCI.35  There are also differences in cell predominance and time of peak numbers of 
cells after injury within species among strains of mice suggesting that genetic variation 
may play a role in the neuroinflammatory response.19,35 These differences among and 
within species present an additional challenge when it comes to unraveling and 
understanding the inflammatory response to SCI and applying therapeutic intervention 
studied in experimental rodent models to canine and human inflammation.  
 Pro-inflammatory cytokines including IL-6, IL-8 and possibly TNFα are 
immediately increased after spinal cord injury in dogs.27,40  These cytokines are thought 
to be produced by microglia.23,40  Interleukin-6 promotes the activation of inflammatory 
macrophages, M1 phenotype.44  The anti-inflammatory cytokine TGF-β is not 
upregulated in dogs until three to four days after injury.  This is similar to humans who 
share peak levels of the pro-inflammatory cytokines IL-6 and IL-8 in CSF after injury 
and a delayed increase in IL-10 and TGF-β.  The anti-inflammatory cytokines have been 
shown to possess neuroprotective qualities as IL-10 knockout mice suffered more severe 
inflammation and injury compared to control animals after artificially induced ASCI.45  
As a result, a therapeutic intervention aimed at altering the balance of cytokine levels 
toward the anti-inflammatory cytokines, IL-10 and TGF-β, to peak earlier in the course of 
the neuroinflammatory response is an interesting consideration.  
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Excitotoxicity 
 Excitotoxicity refers to neuronal cell death secondary to excessive exposure to 
glutamate.6,46  Within the central nervous system, glutamate is the main neurotransmitter 
responsible for synaptic transmission of excitatory impulses between neurons.46,47  After 
transmission, glutamate is removed from the synaptic cleft and extracellular space via 
active transport by adjacent astrocytes and neurons.48  This allows for the recycling of 
glutamate into glutamine and back to glutamate by glial cells and neurons respectively.  
Glutamate uptake also stimulates glycolysis which results in lactate release from 
astrocytes that may be used as an energy substrate by neurons.49  Most importantly, 
glutamate uptake maintains a high intracellular to extracellular concentration gradient, as 
glutamate is toxic to neurons at high extracellular levels.  Maintenance of this gradient is 
dependent upon energy supply.47  During pathological states such as brain or spinal cord 
injury and other neurological diseases, this homeostasis is no longer maintained and 
excitotoxic levels of glutamate may accumulate.   
Ischemia, hypoxia and hypoglycemia are conditions that lead to increased release 
of glutamate or failure of glutamate active transporters and can result in excitotoxic levels 
of the neurotransmitter in the extracellular space.48  Neurotoxic levels of glutamate 
accumulate within the extracellular space within minutes of SCI.6,50  Glutamate, 
administered at quantities consistent with experimental spinal cord injury, has been 
shown to result in significant neuronal cell death.50  Oligodendrocytes are also vulnerable 
to excitotoxic levels of glutamate via AMPA receptors.6,10,47  Extensive demyelination is 
a concerning sequel because a single oligodendrocyte is responsible for myelinating 
several axons.  
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Glutamate was found to be significantly increased in the CSF of dogs obtained via 
lumbar collection following acute and chronic spinal cord injury compared with controls.   
Additionally in this study, increases in glutamate were directly associated with the 
severity of clinical signs.10  It is interesting to note that increased glutamate 
concentrations compared to controls were still detected despite injury occurring up to 
months prior to CSF sampling.  Experimental studies suggest that glutamate levels 
decline to 25% of their peak values within 30 minutes of injury.51  Olby theorized that 
persistent parenchymal compression perpetuated the presence of increased levels of 
glutamate in the case of naturally occurring disc herniation.  The levels detected in the 
CSF of dogs following naturally occurring IVDH were much lower (0.9-20.33 μM) 10 
than the extracellular concentrations found at the site of experimental injury (0.53+/-0.14 
mM) 50,51 and those used to mimic excitotoxic concentations, capable of inducing 
neuronal cell death. However, depending upon the type of injury, these findings may 
support excitotoxicity as a potential target of secondary injury worth directing 
interventional therapy towards in future clinical trials. 
 
Ion Dysregulation 
Studies have shown alterations in Na+, K+ and Ca2+ ions in the area of the lesion 
after experimental SCI.6  Not only are ion concentration gradients affected by direct 
damage to the cellular membrane but Na+/K+ ATPase failure may also occur.  This may 
lead to Na+ influx and cell swelling or cytotoxic edema that not only results directly in 
cell death but also tissue swelling that compromises microvascular perfusion of adjacent 
cells.  Calcium ion influx causes cell death via lipid peroxidation and ROS production.  
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Dysregulation of calcium also causes mitochondrial dysfunction that leads to cell death 
via second messengers such as cytochrome c resulting in apoptosis. 
 
Oxidative Stress and Acrolein Cytotoxicity 
Several of the secondary injury mechanisms previously mentioned including 
calcium influx, excitotoxicity, inflammation and ischemia lead to the production of 
reactive oxygen species (ROS) that induce cellular damage or oxidative stress.11  
Excessive oxidative injury then begins a chain reaction leading to further ROS 
accumulation that can overwhelm the endogenous stores of antioxidants in the tissue.  
These unchecked oxidative reactions such as lipid peroxidation can directly and 
indirectly cause neuronal and glial cell death.   
ROS are free radicals derived from oxygen.  Secondary injury phenomena such as 
calcium influx can lead to the loss of an electron from oxygen, producing superoxide 
radical (O2--).  Superoxide dismutase (SOD) normally squelches this free radical by 
catalyzing its reaction into H2O2 and O2.  In fact, the administration of SOD has been 
shown to provide some benefit after spinal cord ischemia in dogs and rabbits.52 The 
proper storage of iron and other catalyzing metal ions is a key factor in reducing the 
production of free radicals.  If they are not stored and transported properly then they are 
free to catalyze the reactions that produce free radicals including lipid peroxidation.  In 
the ischemic and therefore more acidic environment of injured tissue, iron is freed from 
transferrin (iron transport protein) and ferritin (storage protein) to catalyze ROS 
production reactions.11 The CNS may be especially sensitive to this phenomenon 
compared with other tissues because CNS tissue is rich in iron and cerebral spinal fluid is 
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not able to buffer free iron released after trauma.53   Iron reacts with hydrogen peroxide to 
create hydroxyl radical.  Hydroxyl radical reacts with carbohydrates, DNA and 
membrane phospholipids and disrupts their functions.  The reaction of ROS with 
membrane phospholipids also results in lipid peroxidation or oxidative degeneration of 
lipids.  It is caused by ROS, such as the hydroxyl radical, removing an electron from 
polyunsaturated fatty acids in the cell membrane and leaving behind a carbon-centered 
radical.  These carbon-centered radicals react with oxygen to form peroxyl radicals.  
Peroxyl radicals in turn may destroy membrane proteins including receptors and enzymes 
necessary for cell function or may react with adjacent membrane lipids and continue on 
to self-propagatate a series of these chain reactions.  The cell membrane becomes less 
fluid and therefore leaky to ions.  Not only are the cell membranes directly damaged from 
lipid peroxidation but lipid peroxidation also produces cytotoxic aldehydes such as 
acrolein, malondialdehyde, 4-hydroxynonenal (HNE).  This propagation stops with the 
reaction of two peroxyl radicals with one another or with the help of antioxidants such as 
vitamin E, superoxide dismutase and glutathione reductase.11,53,54   
The α,β-unsaturated aldehyde products of lipid peroxidation including acrolein, 
malondialdehyde, and 4-HNE are toxic to adjacent cells because they create bonds with 
proteins and amino acids in DNA, altering their structure and cellular function.55,56  
Acrolein may also be produced from polyamines such as spermine and spermidine, 
released after RNA injury by hydroxyl radical, making it more abundant than 4-HNE in 
CNS tissue.57,58  Acrolein and 4-HNE have been well documented to be associated with 
the pathological effects of secondary injury in ASCI in experimental studies.59,60  4-HNE 
was found within grey matter immediately after contusive injury and found in white 
 18 
matter tracts later; it was also found at the site of injury immediately but diffused to 
adjacent spinal cord segments 24 hours later.61,62  The author surmised that the cytotoxic 
aldehyde spread to adjacent tissue in time. Acrolein has also been shown to diffuse to 
adjacent healthy tissue at pathological concentrations after incubation with injured spinal 
cord tissue in an ex vivo experiment.63  Luo et al found that acrolein levels increased at 
the injury site 4 hours after the insult, peaked at 24 hours and remained increased for at 
least 7 days.62  Additionally, adjacent segments of cord within 10 mm of the epicenter 
contained increased acrolein levels starting at 24 hours post injury.62  Acrolein is 
estimated to have a longer half-life of 7-10 days than free radicals and is a more volatile 
aldehyde than 4-HNE having been estimated as having 100 times greater intracellular 
reactivity toward nucleophiles.62-67  In toxicity studies, acrolein has been compared with 
hydroxyl radical and hydrogen peroxide and was found to be more toxic than both.58,68  It 
readily reacts with glutathione thereby exacerbating oxidative stress once glutathione 
tissue stores are depleted.66  Due to its ability to damage tissue that was not compromised 
by the primary injury, its longer half-life and high reactivity, it stands to reason that 
scavenging acrolein may be a beneficial therapeutic target of the secondary injury 
cascade.   
Acrolein’s cytotoxicity may be due to its ability to cause ROS production, 
damage DNA, disrupt the function of cellular proteins and deplete endogenous 
glutathione stores.63,69,70  Although the specific mechanisms of action that cause 
acrolein’s toxicity are still being investigated, its cytotoxicity is likely to be partially due 
to its reactivity with nucleic acid residues within proteins and DNA such as cysteine, 
lysine, histidine, and arginine therefore altering or disrupting the transcription or function 
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of proteins.56,71,72  Nakamura recently showed that conjugation of acrolein with 
glyceraldehyde-3-phophate dehydrogenase (GAPDH), by binding with a cysteine active 
site, may be an important mechanism of cytotoxicity.  Using mouse mammary carcinoma 
cells and exposing them to 8uM acrolein, cellular ATP was reduced and the acrolein-
conjugated GAPDH moved from the cytoplasm into the nucleus possibly inducing 
apoptosis.71  Interestingly, an earlier study using acrolein-bathed PC12 cells showed that 
the majority of cell death was due to necrosis rather than apoptosis.73  This toxicity was 
also concentration dependent with 92% of cells dying after being exposed to 100 uM of 
acrolein for 24 hours; 58 and 25% cell death was seen after incubation with 10 uM and 1 
uM respectively.73  Pre-incubation with antioxidant therapy significantly reduced ROS 
production and cell death in this study.  The authors similarly demonstrated that 
antioxidants protected spinal cord neurons from oxidative injury after acrolein 
administration.74  One study quantified ROS production secondary to the administration 
of 25 uM of acrolein to increase by a factor of 1.8 in murine hippocampal cells.75  
Excessive ROS production, as can occur in ASCI, overwhelms the endogenous 
antioxidant capacity of the CNS resulting in oxidative injury of lipids, proteins and 
DNA.11 
Membrane damage may lead to mitochondrial and plasmalemma dysfunction, 
resulting in cell death.67  ROS produced during the secondary injury cascade contribute to 
this dysfunction.11  This is supported by the protection that anti-oxidant therapy has 
provided against membrane damage from acrolein.74  As a result, acrolein’s ability to 
perpetually produce ROS that damage the integrity of the mitochondrial and cell 
membranes has been suggested as a mechanism of its cytotoxicity.76  Within 
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mitochondria specifically, an increased ROS production of 50% was shown after 
exposure to 10 uM of acrolein.73  Furthermore, oxidative injury is likely exacerbated 
because the concentration of mitochondrial endogenous antioxidant, glutathione, is 
reduced upon exposure to acrolein and its resultant increased ROS production.73  
Acrolein has been shown to increase the permeability of neuronal cell membranes in a 
time and dose dependent manner more severely than 4-HNE.74  Additionally, acrolein can 
diffuse to tissue adjacent to the epicenter of a traumatic lesion.  Using a guinea pig SCI 
model, researchers found cell membrane damage 10 mm from the primary injury as well 
as increased levels of acrolein.74,77   
Mitochondria are targets of cytotoxic aldehydes and have been proposed to be an 
important factor in several neurodegenerative diseases.67  The brain and spinal cord have 
little energy reserve therefore under circumstances of increased energy requirements, 
cells become more dependent upon the function of mitochondrial respiration.  
Mitochondrial respiration and energy production are reduced in the presence of acrolein 
and ROS production with spinal cord mitochondria being more sensitive to the toxic 
effects of acrolein than brain mitochondria.67,73,74,78,79  Several mechanisms of action have 
been discussed including the ability of acrolein to bind to a cysteine residue within 
adenine nucleotide translocase (ANT) as ANT activity was significantly inhibited by 
acrolein in guinea pig brain mitochondria.76,78  ANT is thought to be necessary for normal 
mitochondrial electron transport function.  This inhibition of function not only leads to 
decreased energy production for the cell but also results in even more ROS production 
that potentiates the cycle of oxidative stress.62,73  Another mechanism of action attributed 
to acrolein is its effect on the mitochondrial membrane potential necessary for normal 
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function.   Acrolein has been shown to reduce mitochondrial membrane potential in a 
dose-dependent manner.73  Pretreatment with either glutathione or N-acetylcysteine have 
been shown to significantly reduce the effects of acrolein on mitochondrial respiration in 
vitro.67,73  Several of these mechanisms of mitochondrial dysfunction ultimately lead to 
the initiation of apoptosis of the cell. 
Acrolein has been shown to cause hepatocyte destruction not only due to direct 
toxicity of protein adduction but also likely due to its adduction of liver glutathione.80   
This may cause an indirect toxic effect due to the depletion of available antioxidant 
protection as lipid peroxidation has been described to occur secondary to excessive loss 
of glutathione in one study.81  Glutathione is composed of three amino acids including 
glutamate, glycine, and cysteine.82  It acts as an antioxidant transporting free radicals out 
of the cell.82  Glutathione depletion alone without the influence of acrolein has in fact 
been proposed to lead to apoptosis.83  It is well known that glutathione reserves can be 
severely depleted by increased acrolein levels while concurrently causing further ROS 
production.66,73,74,84,85 It has been shown that pretreatment with a low or sublethal level of 
acrolein not only upregulates the endogenous production of glutathione but this increased 
glutathione level becomes protective against subsequent acrolein-mediated injury from an 
additional high dose of acrolein.70,86  Therefore, it is likely that severe glutathione 
depletion after ASCI plays a key mechanistic role in the cytotoxicity of acrolein.70  
It has also been suggested that the macromolecular adducts of acrolein may 
maintain some cytotoxicity.  Each acrolein molecule has two reactive electrophilic 
centers available therefore after adduction of an amino acid at one carbonyl center, the 
other remains available to undergo further addition creating crosslinking of 
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macromolecules.55,56,72,85  Higher cellular glutathione levels before administration of 
acrolein led to reduced protein polymerization via acrolein crosslinking.70 
As previously discussed, the toxicity of acrolein appears to be concentration and 
time dependent and may also depend upon the exposed cell type.  Functionally, acrolein 
has been shown to induce axolemmal injury and reduce axonal conduction in a time and 
concentration dependent manner.59  The level of acrolein administered to cause axonal 
damage was found to be between 50-200 uM.59  It has also been shown to inhibit 
mitochondrial function, lower cellular ATP and induce neuronal cell death in a 
concentration dependent manner.75,78,80,  In cell culture, neuronal membrane damage has 
been detected after exposure to as little as 1 uM of acrolein with the severity of injury 
worsening with rising concentrations.74  Pulmonary arterial endothelial cell death has 
been described to occur with the administration of 25-100 uM of acrolein.66 In respiratory 
epithelium, glutathione was able to trap acrolein and prevent cytotoxicity at levels ≤ 3 
uM.  When the level of acrolein was further increased, glutathione levels decreased and 
cytotoxicity was detected between 3-10 uM of acrolein.  Acrolein levels ≥ 10 uM 
overwhelmed the endogenous protection of glutathione and 80% of the administered 
acrolein was recovered unbound to glutathione.86  The amount of acrolein found in 
normal spinal cord tissue versus the amount endogenously produced after ASCI has not 
yet been determined therefore whether it reaches pathological levels after naturally 
occurring injury remains to be seen.
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CHAPTER 3: CLINICAL STUDY 
 
Urine 3-HPMA Is Increased in Acute Spinal Cord Injury Due to Intervertebral 
Disc Herniation in Dogs 
 
1.1  Introduction 
 
 Acute spinal cord injury (ASCI) occurs in dogs secondary to intervertebral disc 
herniation, fibrocartilagenous emboli and less commonly due to spinal fracture or 
subluxation.  Depending upon the severity of the injury, debilitating neurological deficits 
can persist and may ultimately result in euthanasia.  Surgical decompression of 
intervertebral disc herniation (IVDH) can provide a good to excellent prognosis for 
functional recovery in many of these patients, except for dogs that suffer from loss of 
nociception.   Functional outcome for patients that present with loss of nociception, the 
most severe clinical manifestation of ASCI, carries a more guarded prognosis and has 
been variably reported to be between 25% and 78%.1-5 
 It has been well established that ASCI has two pathophysiological stages of 
injury.6-14  These include the primary injury and the secondary injury cascade.  The 
primary injury includes the initial or mechanical insult to spinal cord parenchyma and 
vasculature.  If it is due to a compressive lesion that persists, such as in the case of a 
herniated disc, then the primary injury phase can be prolonged. The secondary injury is a 
cascade of biochemical events that propagates the damage of adjacent, healthy tissue
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increasing the overall volume of spinal cord tissue that is affected.6-14  Secondary injury 
may be more detrimental to the spinal cord parenchyma than the primary injury itself.14  
This cascade includes ischemia, inflammation, ion dysregulation, excitotoxicity, reactive 
oxygen species production and lipid peroxidation.  These processes ultimately lead to 
tissue necrosis and oligodendrocyte apoptosis.6-14 
 The effectiveness of medical treatments that could be used to compliment surgical 
intervention to improve functional outcome after ASCI has been limited to date.  
However, extensive research into novel therapies to target specific pathways within the 
injury cascade has been performed over the last few decades and promising results using 
experimental models have paved the way for clinical trials in veterinary patients with 
naturally occurring injury. 
 Various biomarkers of ASCI in dogs have been proposed.  Glutamate, a 
neurotransmitter that accumulates and causes excitotoxicity during the secondary injury 
cascade, has been shown to be increased in the cerebral spinal fluid of dogs with ASCI 
after disc herniation and the degree of change appeared to be directly related to the 
severity of the injury.15  Oxidative stress has been shown to be an important component 
of secondary injury in rodent models of ASCI.25-28,35  Urinary isoprostane, which is a 
biomarker of oxidative stress, was found to be higher in dogs with intervertebral disc 
disease (IVDD) compared to dogs undergoing ovariohysterectomy.16  However, further 
aspects of oxidative stress after ASCI have not been investigated extensively in the dog.  
 Acrolein is a reactive aldehyde byproduct of lipid peroxidation, an oxidative injury 
reaction that has been shown to begin soon after injury and continue for approximately 7 
days in a mouse model of ASCI.6  The same study showed that acrolein remained 
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increased beyond the duration of lipid peroxidation before it decreased back to baseline 
levels at approximately 14 days after injury.6  It is extremely cytotoxic and thought to be 
a major cause of tissue damage in the secondary injury cascade.24-26  In fact, acrolein 
scavenging or neutralization has been shown to be neuroprotective in rodent models of 
both ASCI and traumatic brain injury.24,25  Because acrolein is a highly volatile substance 
and forms adducts with cellular compounds, an assay for its direct measurement from 
urine is not currently available.  However, a metabolite of acrolein-glutathione adduct 
found in urine, 3-hydroxypropylmercapturic acid (3-HPMA), has been previously 
quantified for use in human toxicology studies and used as an indirect measurement of 
free acrolein and has recently been shown to increase after spinal cord injury in a rat 
model.18-22,35  The intention of our study was to apply this urine 3-HPMA assay to dogs to 
indirectly quantify acrolein levels resulting from ASCI.  This biomarker could then be 
used to quantify response to treatment in future clinical trials of novel therapeutic 
interventions focused on quenching lipid peroxidation or acrolein trapping.  If a 
correlation between biomarkers of acrolein and clinical outcome can be made, then 
acrolein reduction could become an important target for therapeutic intervention in ASCI.  
As a result, our goal was to evaluate the use of 3-HPMA as a biomarker of naturally 
occurring ASCI in dogs.  Our hypothesis was that the concentration of 3-HPMA found in 
urine of dogs with ASCI due to IVDH would be higher than that of control dogs, and 
would be directly related to the severity of neurological grade.  We also hypothesized that 








 This was a prospective, blinded, controlled study.  Urine from ten client-owned 
dogs with ASCI was collected and analyzed for the acrolein metabolite, 3-HPMA upon 
presentation to Purdue University Veterinary Teaching Hospital and for three consecutive 
days.  Urine from ten dogs with no evidence of disease was analyzed and used as controls.  
This study was approved by the Purdue University Animal Care and Use Committee (# 
1309000935).  Informed consent was obtained from all owners before enrollment in the 
study.   
 Dogs were eligible for inclusion if they suffered an acute, thoracolumbar spinal 
cord injury within 72 hours prior to admission and were classified with grade three 
neurological deficits or higher.  The preoperative neurological status was graded using a 
5 point scale as follows: grade 1, spinal pain only; grade 2, ambulatory paraparesis; grade 
3, non-ambulatory paraparesis; grade 4, paraplegic animals with nociception; and grade 5, 
paraplegia without nociception.  Duration of paraparesis/plegia prior to presentation was 
classified as < 24 hours, 24-48 hours, and 48-72 hours.  Dogs were excluded if they had a 
history of spinal cord disease greater than 3 days, concurrent illness or recently (< 7 days) 
sustained a traumatic injury affecting the body outside of the spinal cord. 
 MRI and/or CT was used to confirm a diagnosis of intervertebral disc herniation 
with spinal cord compression in all dogs but one.  The study design included urine 
collection via expression or catheterization on day 1 (day of presentation), and days 2, 3 
and 4 when possible.   
 Power analysis indicated that a sample size of 10 dogs per group would be 
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necessary to detect a difference of 50% between 3-HPMA levels in urine of dogs 
suffering from ASCI versus urine of control dogs, with an alpha level of significance of 
0.05 and power of 90%. 
 
3-HPMA and Creatinine Assay 
 Three-HPMA was analyzed in urine according to Eckert et al.22  Solid phase 
extraction with Isolute ENV+ cartridges (Biotage, Charlotte, NC) was used to prepare 
each sample before LC/MS/MS analysis.  Each cartridge was conditioned with 1mL of 
methanol, followed by 1mL of water, then 1mL of 0.1% formic acid in water.  A volume 
of 500 µL of urine was spiked with 200 ng of deuterated 3-HPMA (d3-3-
HPMA)(Toronto Research Chemicals Inc., New York, Ontario) and mixed with 500 µL 
of 50 mM ammonium formate and 10 µL of undiluted formic acid.  This mixture was 
immediately loaded onto the prepared ENV+ cartridges.  Each cartridge was washed 
twice with 1 mL of 0.1% formic acid, followed by 1 mL of 10% methanol/90% 0.1% 
formic acid in water.  The cartridges were dried with nitrogen gas and subsequently 
eluted with three volumes of 600 µL methanol + 2% formic acid.  The eluates were 
combined and dried with a rotary evaporation device.  Each sample was then 
reconstituted in 100 µL of 0.1% formic acid before LC/MS/MS analysis. 
 An Agilent 1200 Rapid Resolution liquid chromatography (LC) system coupled to 
an Agilent 6460 series QQQ mass spectrometer (MS) was used to analyze 3-HPMA in 
each sample.  A Waters Atlantis T3 2.1mm x 150mm, 3 µm column was used for LC 
separation.  The buffers were (A) water + 0.1 % formic acid and (B) acetonitrile + 0.1% 
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formic acid.  The linear LC gradient was as follows: time 0 minutes, 0 % B; time 1 
minute, 0 % B; time 9 minutes, 95 % B; time 10 minutes, 95 % B; time 11 minutes, 0 % 
B; time 15 minutes, 0 % B.  Retention time of the 3-HPMA/d3-3-HPMA was 6.8 minutes.  
Multiple reaction monitoring was used for MS analysis.  The 3-HPMA data were 
acquired in negative electrospray ionization (ESI) mode by monitoring the following 
transitions: 220.1⇒91 with collision energy of 5 V and 220.1⇒89 with collision energy 
of 15 V.  The d3-3-HPMA data were acquired in negative electrospray ionization (ESI) 
mode by monitoring the following transitions: 223⇒91 with collision energy of 5 V and 
223⇒89 with collision energy of 15 V.  The jet stream ESI interface had a gas 
temperature of 325°C, gas flow rate of 8 L/minute, nebulizer pressure of 40 psi, sheath 
gas temperature of 250°C, sheath gas flow rate of 7 L/minute, capillary voltage of 4000 V, 
and nozzle voltage of 1000 V.  Creatinine measurement was performed using creatinine 
(urinary) assay kit (Cayman Chemical Co.) according to the accompanied manual.  
Creatinine measurement was performed in order to correct for variations in urine 
concentration between samples.  Urine samples were frozen at -80 °F immediately after 
collection.  They were stored for up to 2 weeks prior to analysis. 
 
Statistical Analysis 
 Urinary 3-HPMA levels were logarithmically transformed to correct the right-
skewness.  A Welch t-test was used to compare geometric means of urinary 3-HPMA 
levels between the affected group and the control group.  A paired t-test was used to 
compare 3-HPMA levels from day 1 and day 2.  Additionally, spearman rank correlation 
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(rs) was used to investigate if a relationship existed between 3-HPMA levels and 
neurological grade, body weight, and duration of injury prior to urine sample collection.  
Mann-Whitney testing was used to compare urinary 3-HPMA of intact versus neutered 
dogs.  Sample size calculations were performed using software available on 
Hedwig.mgh.harvard.edu.  Statistical analysis was performed using software available on 
MedCalc® (Version 12.6.1.0, MedCalc software, Ostend, Belgium).  P < 0.05 was 
considered significant
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 Of the dogs with ASCI, several breeds were represented, including four dachshunds 
and one of each of the following breeds: Pug-Beagle mix, Cocker spaniel, Pekingnese, 
Doberman pincer, Shih tzu and Beagle.  Ages ranged from 1-10 years with a mean of 5.5 
years.  Three neutered males, 1 intact male, 4 spayed females and 2 intact females were 
included. Urine was collected on day 1 in all cases, and on day 2 (n=5) where possible. 
The neurological grade at admission was grade 3 (n=3), grade 4 (n=3) or grade 5 (n=4).  
 The geometric mean concentration of urinary 3-HPMA in ASCI dogs on day 1 of 
8.52 μmol 3-HPMA/g Cre (95% confidence interval (CI) 3.76-19.32) was significantly 
higher than the mean concentration in control dogs of 3.28 μmol 3-HPMA/g Cre  (95% 
CI 2.73-3.94; p = 0.028) (Fig. 1).  The mean urine 3-HPMA from ASCI dogs was 2.6 
(95% CI 1.1 – 6.0) times higher than controls.  No significant difference in concentration 
was appreciated between geometric means of day 1 (12.36 μmol 3-HPMA/g Cre) and day 
2 (7.04 μmol 3-HPMA/g Cre; p = 0.179). 
 A moderate correlation (rs = -0.51, 95% CI -0.86 - 0.18) suggesting an inverse 
relationship between neurological grade and urine 3-HPMA was noted but was not 
statistically significant (p = 0.135) (Fig. 2).  A correlation between the degree of urine 3-
HPMA and the duration of time from initial injury to urine collection was not significant 
(rs = 0.33, 95% CI -0.38 – 0.8; p = 0.349).  Urinary 3-HPMA of intact dogs was 
significantly higher than neutered dogs (p = 0.017) (Fig. 3). 
 One patient with a neurological grade of 5 was euthanized prior to imaging and 
treatment per owner’s request (13.61 μmol 3-HPMA/g Cre at presentation).  Seven of the 
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remaining 9 dogs recovered ambulatory function after surgical decompression. Two dogs 
failed to recover ambulatory function; both were classified with a neurological grade of 5 
at presentation.  One of these two dogs developed myelomalacia (initial, 2.75 μmol 3-
HPMA/g Cre) and was euthanized soon after surgery.  The other dog persistently lacked 
nociception on recheck exam, 1 year after surgical decompression (initial, 4.20 μmol 3-
HPMA/g Cre).   The median urine 3-HPMA of the 7 dogs that recovered ambulation 
post-operatively was 5.80 μmol 3-HPMA/g Cre.   







Figure 1.  Urine 3-HPMA in ASCI dogs (n=10) is significantly higher than in control 
dogs (n=10), p<0.03.  The top, middle and bottom line of the box correspond to the 75th 
percentile, the 50th percentile (median) and the 25th percentile respectively.  The asterisk 







Figure 2.  Urine concentrations of 3-HPMA versus neurological grade.  Note the slight 
inverse relationship between severity of neurological grade and severity of urine 3-
HPMA concentration.  Horizontal line denotes the median and the asterisk corresponds 








Figure 3.  Urine 3-HPMA concentrations in intact dogs were significantly higher than 
neutered dogs, p<0.02.  The horizontal line denotes the median and the asterisk 
corresponds with an outlier (157.36 μmol 3-HPMA/gram creatinine.
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The current study showed a statistically significant difference in urine 3-HPMA 
from dogs affected with ASCI due to IVDH compared with control dogs, thereby 
providing evidence for using urine 3-HPMA as a biomarker of ASCI in dogs.  This is 
consistent with the known role of lipid peroxidation in secondary injury.  3-HPMA is the 
first assay used in dogs to indirectly assess acrolein concentration by measuring an 
acrolein-glutathione adduct after naturally occurring ASCI.  Considering that acrolein is 
cytotoxic, it is likely that the increased concentrations of acrolein play a clinically 
relevant role in secondary injury in dogs, and may warrant therapeutic intervention.  It is 
also important to note that a previous study in rats found that urine 3-HPMA values were 
2.6 times lower than concurrent spinal cord tissue protein-acrolein values in the same 
individuals at the same time point.35  The author theorized that a dilutional effect 
occurred in the systemic circulation from the area of injury.  This would suggest that the 
concentration of acrolein in the spinal cord tissue is much higher than what the urine 
samples reflect.  Studies in people have established plasma acrolein as a sensitive 
biomarker for cerebrovascular accidents and studies in animal models of brain and spinal 
cord injury have shown that sequestering aldehydes with drugs that reduce acrolein 
concentration in the central nervous system (CNS) is neuroprotective.24,25,27,29-31   
Establishing a biomarker for acrolein concentration in dogs after ASCI may aid in the 
development of neuroprotective agents after naturally occurring ASCI. 
 There was some degree of overlap between the 3-HPMA concentrations from the 
affected dogs and the control subjects. The purpose of this biomarker is not to establish a 
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diagnosis of spinal cord injury for dogs.  Instead, the goal is to establish this as a 
companion analytical tool to identify and further characterize ASCI.  Furthermore, we 
intend to utilize urine 3-HPMA in future studies as a measure of acrolein-adduct 
reduction with treatment using drugs that suppress lipid peroxidation and/or scavenge 
acrolein.  Serial sampling may be required with the baseline being established for each 
individual as the first sample taken after injury. This acrolein biomarker may be of use in 
understanding the success or failure of any putative ASCI medical therapy, as well as its 
mechanism of action.    
 The concentration of 3-HPMA from exogenous sources has not yet been previously 
established and exogenous acrolein may partially contribute to the overlap seen between 
the control and affected groups.  Acrolein is not only endogenously produced via lipid 
peroxidation but is present in the environment as a product of combustion.18  It is an air 
pollutant associated with diesel engine and industrial emissions.  Acrolein is present in 
small amounts in various foods and quite high levels are found in cigarette smoke.18-20  It 
has been well established that the level of 3-HPMA in the urine of smokers is 
significantly higher than non-smokers.19,20  Individual variation of exogenous acrolein is 
likely due to variable environmental exposure.  Data on diet and second hand smoke 
exposure were not available in this study, but would be warranted in future studies. 
 An increased urine 3-HPMA concentration was not directly correlated with a more 
severe neurological grade as was hypothesized.  Instead, although an inverse correlation 
was not statistically significant, it is interesting to note that the highest 3-HPMA 
concentrations were seen in dogs that presented with the least severe neurological grade.  
The relatively lower concentrations of 3-HPMA in the present study seen in clinically 
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more severely affected dogs could be due to glutathione depletion rather than a relatively 
lesser degree of production of acrolein.  In people with late stage Alzheimer’s disease, 
glutathione transferase activity was decreased in certain areas of the brain but unchanged 
elsewhere in the brain.23  This was postulated to be due to glutathione depletion in 
pathologic areas of the brain while spared tissue maintained its ability to detoxify.31  This 
may apply to clinically less affected ASCI patients having more functional tissue to 
produce glutathione to bind to acrolein.  Similarly, another study found an inverse 
correlation with lesion severity of cerebral strokes in people.  Urinary 3-HPMA levels 
were lower in stroke patients than in controls and concentrations were significantly lower 
if the lesions were ≥ 1cm compared with lesions < 1cm.32  It has been suggested that 
acrolein preferentially reacts with glutathione rather than the lysine residues in proteins 
and that glutathione plays a vital role in the endogenous detoxification of acrolein.28  It 
has also been shown that plasma acrolein-protein adducts increase after stroke, 
supporting acrolein production overwhelming the glutathione stores of the CNS so that as 
glutathione-acrolein adducts decline, protein-acrolein adducts climb.33  Concurrent 
measurement of the plasma protein-acrolein concentrations of the patients in our study 
would have assisted in determining if this relationship exists after ASCI in dogs.   
 Another possible cause for the relatively lower levels of urine 3-HPMA in more 
severely affected dogs in this study is that CNS glutathione may also be depleted by 
excessive glutamate release during secondary injury.   Glutamate accumulates after ASCI 
and is known to be excitotoxic to adjacent neurons but it can also prevent the uptake of 
cysteine, which is the rate limiting amino acid necessary for the production of 
glutathione.34  Glutamate concentrations have been shown to increase in the lumbar CSF 
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of dogs after ASCI in direct relationship to the degree of clinical neurological grade.15  
Further studies into the relationship between the severity of ASCI and urine 3-HPMA 
levels in dogs and possibly their relationship to glutamate concentrations are warranted. 
 It was also interesting to note that urine 3-HPMA concentrations from the dogs that 
did not recover neurological function post-operatively (median 3.48 μmol 3-HPMA/g 
Cre) were lower than concentrations from dogs that did recover function (median 5.80 
μmol 3-HPMA/g Cre).  In fact, the lowest level (2.75 umol 3-HPMA/g Cre) was from the 
only dog that developed myelomalacia post-surgical decompression.  This finding poses 
the question, are dogs with lower inherent glutathione levels at greater risk for more 
severe sequela to spinal cord injury such as myelomalacia or is the injury and therefore 
acrolein production so severe that the glutathione level is more greatly depleted, therefore 
leading to a lower urine 3-HPMA value?  This was not statistically analyzed due to the 
low number of dogs that failed to recover function (n=2), however it may be of value to 
investigate if the degree of urine 3-HPMA might serve as a prognostic indicator of 
outcome in future studies.  Additionally, measuring whole blood glutathione in future 
studies of naturally occurring ASCI and comparing these findings with urine 3-HPMA 
may be beneficial in assessing the degree to which glutathione depletion plays in the 
ultimate severity of secondary injury. 
 The urine 3-HPMA of intact dogs (2 females, 1 male) was significantly higher than 
that of neutered males and females, which was not expected.  This finding has not 
previously been reported.  The urine 3-HPMA assay has not previously been evaluated in 
a sexually altered population as it has only been performed in humans and rat studies 
using intact specimens.19,35  Had our sample size been larger, multivariate analysis could 
 50 
have been used to investigate whether urine 3-HPMA was most strongly associated with 
neutering status, or factors such as neurological grade.  Future studies are required to 
confirm or reject an association with neutering status. 
 Limitations of this pilot study included the inability to analyze data within 
subgroups, such as degree of urine 3-HPMA versus neurological outcome due to sample 
size.  Similarly, the lack of urine samples following presentation for several consecutive 
days affected our ability to find a statistical difference in urine 3-HPMA over time after 
surgical decompression due to inadequate power of analysis.  Because our study design 
selected for dogs with more severe neurological deficits by including grades 3-5 only, we 
cannot apply the findings to dogs suffering from ASCI with a neurological grade of 1 or 2.
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Urine 3-HPMA, a metabolite of acrolein, is a valid biomarker of ASCI in dogs; 
associations with factors such as duration and severity of injury and neutering status 
warrant further investigation.  This assay allows for an indirect but quantitative measure 
of acrolein that can be used in future studies of pharmaceutical interventions that target 
lipid peroxidation and/or drugs that sequester acrolein.  The ability to measure the effect 
of a targeted treatment in the secondary injury cascade could support a cause and effect 
relationship and isolate acrolein and its reduction as an effective interventional focus in 
the ongoing battle to reduce the severity of the lesion and long-term outcome after ASCI 
in dogs and humans.  If a correlation between treatment and urine 3-HPMA is validated, 
then the assay could be used in an individual to better evaluate treatment and to alter 
treatment dosages based upon changes in the urine 3-HPMA level.
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Antioxidant Therapy    
As previously discussed, antioxidant therapy has been shown to reduce acrolein 
induced injury and cell death of neurons demonstrating that oxidative injury has a chief 
mechanistic role in the toxicity of acrolein.1   
Recently, rapamycin has been shown to reduce acrolein-induced apoptosis of 
male germ cells.  Rapamycin reduced ROS production, increased the ratio of Bcl2/Bax 
mRNA and proteins and protected mitochondrial membranes.  The authors suggested that 
one of the mechanisms of action responsible could be the known upregulation of 
expression of antioxidant genes that occurs with rapamycin therapy.2  Rapamycin, an 
mTOR inhibitor, has several other clinical effects in the body complicating its clinical 
use.  It is currently used in human transplant patients as an immunosuppressant and it can 
also affect insulin sensitivity.  Rapamycin is being investigated as a therapy in several 
other human diseases in canine models including osteosarcoma and glycogen storage 
disease type IIIa and some pharmacokinetic analyses have been performed.3,4  Further 
investigation into its efficacy and safety for use after ASCI may be warranted. 
In another study, caffeic acid, a natural, food-derived antioxidant, protected 
hippocampal neurons from acrolein induced ROS production, glutathione depletion and 
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cell death.5  Only limited investigation into caffeic acid has been performed to date 
therefore further studies are needed. 
Vitamin E is an important antioxidant that acts by reacting directly with ROS, 
donating a hydrogen ion and breaking the cycle of lipid peroxidation.  Each α-tocopherol 
molecule, located within the plasmalemma, traps two peroxyl radicals.  It competes with 
lipid substrate and binds at a rapid rate making it an effective antioxidant.6,7 It has been 
well established that vitamin E is necessary to normal neurological function and animals 
and humans with vitamin E deficiency may develop a distal sensory axonopathy and 
secondary demyelination; 8,9 however, it may take weeks for concentrations within the 
nervous system to increase with supplementation making its use for ASCI impractical 
and ineffective.8  It may however be beneficial to consider regular vitamin E 
supplementation for populations (e.g. chondrodystrophic dogs) who are at greater risk for 
IVDH. 
One of the only studies to address the oxidative stress of secondary injury from 
ASCI in dogs looked at the administration of N-acetylcysteine and its association with 
neurological outcome and 15F2t isoprostane excretion.10  One IV dose of N-
acetylcysteine, a precursor of glutathione, was administered to dogs before surgical 
decompression to dogs with intervertebral disc extrusion.   There was no difference in 
15F2t isoprostane levels or neurological outcome between treated and control groups.10 
The authors described several limitations that could have contributed to the lack of 
efficacy seen in the study: the dose, distribution into the central nervous system as well as 
the fact that only one dose of one type of antioxidant was administered.  Although the 
half-life of ROS is relatively short, lipid peroxidation reactions are self-perpetuating once 
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a certain threshold has been reached and endogenous glutathione stores are depleted.  
ROS are therefore continually produced and oxidative stress continues to be a concern for 
up to a week likely secondary to the lingering aldehyde products of lipid peroxidation.  
Therefore, it is possible that subsequent doses of N-acetylcysteine would have been 
beneficial.  Additionally, a study using mouse mammary carcinoma cells found that N-
acetylcysteine fully protected cells against acrolein-mediated toxicity suggesting that the 
antioxidants benefit may be due to acrolein attenuation rather than removal of hydroxyl 
radical alone.11  The authors went on to cite their unpublished findings of decreased 
protein-conjugated acrolein and brain infarct lesion size reduction in mice after use of N-
acetylcysteine.  The distribution of N-acetylcysteine into CNS tissue is not definitively 
supported.  One study showed that it is distributed into many tissues of mice except for 
the brain and spinal cord;12  however, another study in mice showed increased 
parenchymal concentrations of N-acteylcycteine after intravenous injection that supports 
its ability to cross the BBB.13  Due to the question of CNS distribution, N-acetylcysteine 
was not chosen as a therapy in our follow up study.  However, further investigation into 
its ability to prevent acrolein-mediated injury along with its concurrent ability to 
scavenge ROS may be warranted.   
Despite success in experimental studies, no antioxidant has yet been shown to 
change clinical outcome after ASCI in dogs.  Interest in high dose methylprednisolone 
(MP) came from experimental cat models of SCI that supported MP as an inhibitor of 
lipid peroxidation.14 High dose MP has been investigated in several prospective placebo-
controlled human trials (National Acute Spinal Cord Injury Study [NASCIS]) for its 
antioxidant properties and its improved functional outcome if administered within 8 
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hours of injury was confirmed.15   This benefit was dose and time dependent as no 
improvement was seen if MP was administered after 8 hours.  Also, questions regarding 
the accuracy of the data analysis have been raised therefore the results of the studies 
remain controversial.16  Significant neurological improvement using high dose MP has 
not yet been shown in dogs after ASCI therefore it is less commonly used in veterinary 
medicine due to the concern that the risk to benefit ratio is too great.17  
Previous attempts of therapeutic intervention with anti-oxidants after ASCI in 
rodent models have not significantly improved outcome; however, acrolein scavenging 
and/or lipid peroxidation suppression may provide a more realistic target for dogs after 
ASCI due to their timeline of onset and referral.  As previously stated, although both lipid 
peroxidation and acrolein concentration begin to climb within hours of injury, they 
remain increased for 7 and 14 days respectively.16  Because most dogs present for 
medical and surgical treatment within 1-5 days of injury, intervention targeted at 




 Due to the well-established cytotoxicity of acrolein as well as the lack of clinical 
efficacy of ROS scavengers after ASCI thus far, acrolein trapping has become a focus of 
experimental research to reduce the severity of secondary spinal cord injury.  A 
therapeutic acrolein scavenger that reacts with this toxic carbonyl more quickly than cell 
macromolecules could spare the function of cell proteins and nucleic acids and allow for 
the excretion of non-toxic drug-adducted carbonyl.18  It stands to reason that the 
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relatively longer half-life of acrolein when compared to ROS would provide a larger 
window of opportunity for therapeutic intervention to break the cycle of oxidative stress.  
Furthermore, scavenging acrolein and other aldehydes along with the use of direct 
antioxidants may provide a complimentary approach to reducing oxidative stress.   
Phthalazine drugs such as hydralazine and dihydralazine have been proven to scavenge 
acrolein and acrolein-protein adducts efficiently and rapidly.18,19   Several studies have 
demonstrated hydralazine’s ability to mitigate acrolein-mediated cell injury in PC12 cells 
and cultured hepatocytes.19-21  An ex-vivo experiment using guinea pig spinal cords 
produced convincing results that hydralazine reduced secondary injury after spinal cord 
tissue compression compared with controls.22 
Although hydralazine is a drug that has been used in dogs for other purposes and 
its pharmacokinetics have been described, there are several limitations to its use as an 
acrolein scavenger in this species.  Hydralazine has historically been used as an effective 
afterload reducer and anti-hypertensive agent in dogs with congestive heart failure but 
has mostly been replaced by safer more preferable options.  The dose range used in dogs 
with congestive heart failure is 0.5-2.0 mg/kg, and it is recommended to start at the low 
end of the dose range with slow titration to effect as severe hypotension may occur even 
at recommended dosages.23  This adverse effect would be quite undesirable because 
maintaining normotension in the face of neurogenic shock and loss of autoregulatory 
mechanisms after ASCI is an important component of current standard therapy, and 
would also complicate anesthesia for surgical intervention.  Reducing spinal cord 
perfusion even further after injury-induced vascular compromise should be avoided as a 
therapeutic side effect.  Furthermore, the cardiovascular effects of hydralazine in dogs are 
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long lasting (11-13 hours) relative to the plasma half-life (20-50 minutes) due to either 
the drug binding to smooth muscle in arterioles or possibly due to metabolite activity.24  
Therefore, attempting to maintain plasma concentrations high enough to scavenge 
acrolein would likely result in prolonged risk.   
As previously discussed, the concentration of acrolein that is attributed with 
causing more tissue damage than the primary injury and other aspects of secondary injury 
is currently unknown.  However, Hamann has estimated that tissue levels of acrolein may 
exceed the concentration of hydralazine that can be administered to scavenge it.25  
Hamann estimated that CNS tissue levels likely reach 1-5 nmol/mg of protein.22  This 
would equate to 100-500 umol/L.  It is known that hydralazine traps acrolein in a 1:1 
ratio;21 however, antihypertensive doses of hydralazine reach estimated in vivo 
concentrations of 0.5-1.0 umol after IV administration.26  Furthermore, the drug is highly 
protein bound making the plasma levels low at therapeutic doses and tissue to blood 
ratios lowest in the brain due to poor lipid solubility.27  
Another limitation to the use of hydralazine is associated with the theory that 
cross-linking of acrolein adducts in addition to free acrolein alone is partially responsible 
for acrolein-induced toxicity.  Using bovine pancreas ribonuclease A as a model protein, 
hydralazine has been shown to inhibit cross-linking of acrolein adducts if administered 
within 30 minutes of acrolein exposure but was not effective if administered after 90 
minutes.28   Depending upon the degree of contribution that cross-linking makes to 
acrolein toxicity, delayed therapy with a scavenger like hydralazine may or may not 
effectively reduce acrolein-induced injury.  Furthermore, hydralazine did not prevent 
glutathione depletion or increased extracellular acrolein concentration in mouse 
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hepatocytes.28  The author therefore suggested that free acrolein scavenging is not the 
primary mechanism of cell protection with hydralazine, but rather concluded that 
intracellular acrolein-protein adduct trapping is its main mechanism of action.28  Trapping 
free acrolein may not be clinically necessary to its efficacy against acrolein–induced 
cytotoxicity as MESNA (sodium 2-mercaptoethanesulfonate) is a better extracellular 
scavenger of free acrolein but did not protect cultured hepatocytes as well as hydralazine 
in one study when hydralazine and acrolein were given concurrently.18,28  Furthermore, 
acrolein-protein trapping may come with subsequent risks including the induction of an 
autoimmune reaction to the hydralazine bound acrolein-protein adduct acting as an 
antigen to B cells.29 Therefore, delayed hydralazine administration as would occur after 
naturally occurring ASCI, lack of glutathione sparing and delayed immune mediated 
sequela may be limitations to its clinical use. 
Dihydralazine is structurally similar to hydralazine and could be a more efficient 
scavenger due to a second hydrazine group with which to bind with acrolein.25  However, 
the only pharmacokinetic study that has assessed the concentration of dihydralazine in the 
cerebrospinal fluid of dogs found no drug after IV administration of 5 mg/kg and 7.5 
mg/kg.30  Because these acrolein scavengers are expected to work at the site of injury in 
the CNS, it would be prudent to ensure that hydralazine and/or dihydralazine cross the 
blood brain barrier in dogs and reach therapeutic tissue concentrations before their 
experimental use as acrolein scavengers in dogs is assessed.  Based upon assessment of 
the current knowledge regarding the pharmacokinetics of hydralazine and its effects on 
the cardiovascular system, dihydralazine is also likely to cause severe hypotension before 
reaching adequate tissue concentrations in the CNS to scavenge acrolein.  It is suspected 
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that after trauma, extensive inflammation would increase the permeability of the barrier 
and thus make entry of the drug into the CNS more likely but the extent of which is 
currently unknown.  
Phenelzine is a monoamine oxidase inhibitor with a hydrazine group capable of 
scavenging reactive aldehydes.  Furthermore, its functional inhibition of amine oxidases 
may provide another mechanism of neuroprotection by reducing the production of 
acrolein from polyamines such as spermine.31  Phenelzine at a dose of 15 mg/kg/day for 7 
days provided significant neuroprotection in a gerbil model of ischemic brain infarction.31  
Additionally, phenelzine sequestered acrolein and provided greater than 95% protection 
from LDH release in a retinal cell line.31  Phenelzine may hold some advantage over 
hydralazine in vivo.  In people, the half-life of phenelzine is longer at 11.6 h (Nardil) than 
hydralazine (0.5-1 h).26  Also, it may be possible to reach a higher concentration of 
phenelzine in spinal cord tissue without the adverse effect of hypotension that 
hydralazine induces, however its pharmacokinetics are not yet well known in dogs.  Side 
effects are described but the overall tolerability of phenelzine is not well characterized, as 
the drug is not regularly used in veterinary medicine.  Subcutaneous injections of 2 
mg/kg/day for 3 days led to hyperexcitability and agitation in beagles.32  Tremors and 
cerebellar ataxia are reported to occur at a single dose greater than 5.5 mg/kg and at doses 
of 12 mg/kg for 3 days respectively.33,34  Although a relatively short course of phenelzine 
would be required to scavenge acrolein, the dose required to effectively scavenge 
endogenously produced acrolein after ASCI is not known and one should be aware that 
an experimental model using dogs caused severe cerebellar nuclei necrosis, cortical 
demyelination and convulsions with high doses (12 mg/kg to 20 mg/kg) and with chronic 
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administration (11 weeks).34   Additionally, concurrent use of phenelzine and with local 
analgesics or systemic anesthetics may cause hepatic failure in people.35  Consuming 
foods with tyramine may also lead to hypertensive crisis therefore the diet should be 
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 In summary, the secondary injury cascade created after ASCI is exceptionally 
complicated and multifactorial making the use of only one therapeutic compound to 
lessen its deleterious effects less conceivable.  However, if one could target a major 
component of this cascade that might reduce the propagation of other reactions then 
improved outcome may be achieved.   For this reason, lipid peroxidation and acrolein 
production are two aspects of the cascade that may make for profitable targets.    
We have shown that 3-HPMA, a metabolite of acrolein is increased after naturally 
occurring ACSI in dogs.  Although our initial plan was to perform a clinical trial with an 
acrolein scavenger, after extensive investigation (described previously) the drug options 
and presumed doses required to lower acrolein levels were not considered to be 
adequately safe for our veterinary patients.  Advances in targeted nanocarriers for 
phthalazine drugs or the creation of safer derivatives may allow for their use in the future, 
as proof of principal for their mechanism of action has already been established.1  For the 
current study, a therapeutic intervention that suppresses lipid peroxidation and reduces 
acrolein production was instead used in the follow up study in lieu of phthalazines. 
    72




UDCA Neuroprotection/A Novel Use for Ursodeoxycholic Acid 
Ursodeoxycholic acid (UDCA) is an endogenous bile acid that has been shown to  
protect hepatocytes in cholestatic liver disease in dogs and humans.2-5  UDCA is 
conjugated with taurine or glycine after oral ingestion to form tauroursodeoxycholic acid 
(TUDCA) and glycoursodeoxycholic acid (GUDCA) respectively.  UDCA is currently 
used commonly in veterinary and human medicine for cholestatic disease, hepatic 
cirrhosis and other liver diseases and is considered to be safe and effective in this setting.  
However, to the author’s knowledge, it has not been used for acute CNS injury or 
neurodegenerative disease in dogs.  Experimentally, it has been shown to be 
neuroprotective in Alzheimer disease and Huntington disease models as well as retinal 
degeneration and traumatic brain injury.6-8  UDCA has more recently been evaluated for 
safety and tolerability in 18 humans with amyotrophic lateral sclerosis (ALS).  It was 
found to be very safe at doses higher than the standard dose range and was distributed 
into the CSF in a dose dependent manner.8 Rodrigues has similarly reported detecting 
significantly increased levels of TUDCA in the brain of rats and mice after IV 
administration.9  The concentration of UDCA required to cause a beneficial effect in 
various naturally occurring CNS diseases is not yet well established however, recently, a 
new formula of UDCA has been created that allows for UDCA to accumulate at a greater 
concentration in plasma and therefore the CNS.10  Although not significant, longer 
survival times and a slower rate of progression of neurological decline were noted in a 
recent randomized cross-over trial using the solubilized form of UDCA in ALS patients, 
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though a statistical conclusion could not be made regarding its efficacy due to a high 
attrition rate.11   
Additional support for further investigation into the use of UDCA in CNS disease 
has been established due to the neuroprotective effects seen in experimental ASCI and 
stroke models in rats.  It has been shown that TUDCA protected rat cortical neurons from 
the effects of glutamate excitotoxicity when pretreated with a sufficient concentration of 
TUDCA.12  After experimentally induced SCI, treatment with 200 mg/kg of UDCA daily 
until sacrifice reduced neuronal necrosis and apoptosis and improved functional outcome 
in rats.13  TUDCA administered 1hour after middle cerebral artery occlusion protected rat 
neurons from cell death and substantially decreased the size of the ischemic infarct.9   
Treatment with 100 mg/kg of TUDCA up to 6 hours after acute hemorrhagic cerebral 
infarction reduced the lesion volume by up to 50% in rats.9  In this study and in another 
study using an ischemic stroke model, neurological deficits were significantly improved 
in TUDCA treated rats compared to controls.9,14  
The neuroprotective mechanism of UDCA is not completely known however it is 
thought to be related to its ability to stabilize cell and mitochondrial membranes thereby 
preserving mitochondrial function and preventing apoptosis induction.9,14,15  UDCA 
prevents the production of ROS and inhibits lipid peroxidation and glutathione depletion 
in neuron cell culture.15  In addition to its ability to suppress lipid peroxidation and 
directly reduce ROS production, UDCA has also been shown to reduce the effects of 
oxidative stress by increasing glutathione production through the upregulation of gene 
transcription in cultured hepatocytes and retinal cells.4,16,17   
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It is possible that UDCA may block the action of acrolein through its ability to 
stabilize mitochondrial membranes and directly prevent ROS production.  Mitochondrial 
dysfunction is thought to be an important component in the induction of apoptosis.  In a 
cell model of Huntington’s disease, Rodrigues showed disruption of the outer 
mitochondrial membrane and mitochondrial swelling can lead to cytochrome c efflux that 
induces caspase activation and apoptosis.  TUDCA was able to significantly protect 
neuronal cells from apoptosis via stabilizing the mitochondrial membrane by reducing 
membrane oxidative injury/ROS production and membrane depolarization and, therefore, 
completely abolishing cytochrome c efflux from mitochondria.6   Maintaining 
mitochondrial integrity and function was also a component of the proposed mechanism of 
action responsible for neuroprotection seen with UDCA after SCI in rats.13   Several anti-
apoptotic molecular mechanisms have been proposed including increased production of 
Bcl-2, blocked translocation of Bax protein into the mitochondria and inhibited release of 
cytochrome c.8,9,13,14   
Lipid peroxidation is a self-perpetuating reaction that leads to damaged cell and 
mitochondrial membranes, persistent ROS production and the production of acrolein and 
other toxic aldehydes.  As a result, the ability of UDCA to suppress lipid peroxidation 
could be very beneficial in mitigating the effects of secondary injury after ASCI.  UDCA 
has been shown to suppress lipid peroxidation in an experiment using a human bile model 
and in the liver of rats after common bile duct ligation.3,5 The component of lipid 
peroxidation that the author is most interested in is the reduction of acrolein production 
by UDCA.  We are currently studying if the administration of UDCA at 5-15 mg/kg/day 
for 7 days will lower urine 3-HPMA levels of dogs with naturally occurring ACSI.  This 
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is the standard therapeutic dosing currently used in veterinary medicine for 
cholangiohepatitis.18 Data collection is in progress and results are pending data analysis.  
Although much higher dosing may be required to reach adequate UDCA concentrations 
to cause an effect in CNS tissue, this dose was chosen in our baseline pilot study because 
it is extremely well tolerated in dogs.  It is likely that higher doses will be well tolerated 
in dogs based on safety and tolerability studies in humans however further investigation 
is required to confirm this in dogs.  It has been shown that administering a dose of 50 
mg/kg to humans for over 3 weeks was safe and well tolerated.8  The adverse events 
reported were low grade, mild and mostly gastrointestinal in nature including 
constipation, loose stool, nausea and abdominal bloating.8  UDCA was also shown to 
cross the blood brain barrier in humans in a dose-dependent manner.  Mean CSF 
concentration after oral dosing of 50 mg/kg were significantly higher than after 15 mg/kg, 
producing CSF concentrations of 191.11 nmol/L and 86.69 nmol/L respectively.8   
Therefore, if no change in urine 3-HPMA is seen in our pilot study after administration of 
UDCA, it should be considered that the CNS tissue concentration may not be adequate 
and a dose increase could be considered.  Additionally, use of the new solubilized form 
could be considered.  Determination of UDCA concentration in CSF or CNS tissue would 
be ideal however may not be easily obtained due to invasiveness of testing in client-
owned patients with naturally-occurring injury. 
The toxicity of acrolein is also reduced by UDCA via its ability to up-regulate 
transcription of endogenous glutathione in several cell types.  As previously discussed, a 
component of acrolein-induced cytotoxicity can be attributed to its ability to deplete 
glutathione.  Evidence to this protective mechanism of action was demonstrated by an 
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experiment using cultured neurons whereby increased glutathione concentration provided 
protection against acrolein-induced neuronal cytotoxicity.19   Detoxification by UDCA 
was accomplished through conjugation of acrolein by glutathione that prevented acrolein 
from otherwise reacting with and disrupting cellular proteins and DNA.19 UDCA has also 
been shown to reduce the effects of oxidative stress by increasing glutathione production 
through the upregulation of gene transcription in cultured hepatocytes, retinal cells and 
cultured neurons.4,15-17,19  Therefore, even if the level of acrolein is not secondarily 
reduced by UDCA through suppression of lipid peroxidation then the toxicity of acrolein 
may still be mitigated by its use.  An investigation into the neurological outcome after 
UDCA therapy is therefore warranted regardless of the results of change of urine 3-
HPMA levels.   Additionally, it would be beneficial to measure whole blood glutathione 
concentrations in these dogs before and after UDCA administration and compare these 
results with urine 3-HPMA results.  If urine 3-HPMA levels do not decline after UDCA 
treatment, and if glutathione levels increase, then increased glutathione transcription 
secondary to treatment administration could be supported.
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